NetworkNewsBreaks – BriaCell Therapeutics Corp.
Post# of 69
(Total Views: 200)
Posted On: 02/19/2019 3:48:26 PM
NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) to Present Clinical and Scientific Findings at Key Oncology Conferences
BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, today announced that it will present clinical and scientific findings at key oncology conferences. According to the update, the company was selected to present a poster at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, to be held in San Francisco, California from February 28 to March 2, 2019. The poster will highlight findings related to the mechanism of action of BriaCell’s lead candidate, Bria-IMT(TM), as well as BriaDX(TM), the Bria-IMT(TM) companion diagnostic test and Bria-OTS(TM), the company’s off-the-shelf personalized immunotherapy. In addition, BriaCell Founder and Director Dr. Charles L. Wiseman will be featured as a keynote speaker at the 10th Euro Breast Cancer Summit to be held in Paris, France on March 20 – 21, 2019. The company has also been accepted to present a poster at the Annual Meeting for the American Association for Cancer Research (“AACR”) to be held at the Georgia World Congress Center in Atlanta, Georgia from March 29 – April 3, 2019. The poster will summarize molecular and clinical findings that support the advancement of the Bria-OTS(TM) program.
“An estimated 42,000 women will die of breast cancer in 2019 in the U.S. alone, indicating a substantial unmet medical need for a large patient population whose tumors had become resistant to chemotherapy or other therapeutic regimens,” BriaCell President and CEO Dr. Bill Williams stated in the news release. “Currently, there are no effective treatment options for these patients, leaving them with a very poor prognosis and a grim survival outlook. We are excited to share our findings with the scientific and medical community at ASCO-SITC Clinical Immuno-Oncology Symposium and the AACR meeting. We believe that our unique approach is promising and supports personalizing our immunotherapy to match individual patients. HLA typing may serve as a companion diagnostic test, BriaDX(TM), to determine the best match for Bria-IMT(TM) and for Bria-OTS(TM), our off-the-shelf personalized immunotherapy, which is under development for breast cancer patients. Bria-OTS(TM) has the potential to stimulate the immune system in a manner tailored to the patient without the complexities associated with other personalized therapies, to bring hope to advanced breast cancer patients with few effective treatment options. Further studies are merited and in progress, especially for our ongoing combination study of Bria-IMT(TM) with KEYTRUDA®.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, today announced that it will present clinical and scientific findings at key oncology conferences. According to the update, the company was selected to present a poster at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, to be held in San Francisco, California from February 28 to March 2, 2019. The poster will highlight findings related to the mechanism of action of BriaCell’s lead candidate, Bria-IMT(TM), as well as BriaDX(TM), the Bria-IMT(TM) companion diagnostic test and Bria-OTS(TM), the company’s off-the-shelf personalized immunotherapy. In addition, BriaCell Founder and Director Dr. Charles L. Wiseman will be featured as a keynote speaker at the 10th Euro Breast Cancer Summit to be held in Paris, France on March 20 – 21, 2019. The company has also been accepted to present a poster at the Annual Meeting for the American Association for Cancer Research (“AACR”) to be held at the Georgia World Congress Center in Atlanta, Georgia from March 29 – April 3, 2019. The poster will summarize molecular and clinical findings that support the advancement of the Bria-OTS(TM) program.
“An estimated 42,000 women will die of breast cancer in 2019 in the U.S. alone, indicating a substantial unmet medical need for a large patient population whose tumors had become resistant to chemotherapy or other therapeutic regimens,” BriaCell President and CEO Dr. Bill Williams stated in the news release. “Currently, there are no effective treatment options for these patients, leaving them with a very poor prognosis and a grim survival outlook. We are excited to share our findings with the scientific and medical community at ASCO-SITC Clinical Immuno-Oncology Symposium and the AACR meeting. We believe that our unique approach is promising and supports personalizing our immunotherapy to match individual patients. HLA typing may serve as a companion diagnostic test, BriaDX(TM), to determine the best match for Bria-IMT(TM) and for Bria-OTS(TM), our off-the-shelf personalized immunotherapy, which is under development for breast cancer patients. Bria-OTS(TM) has the potential to stimulate the immune system in a manner tailored to the patient without the complexities associated with other personalized therapies, to bring hope to advanced breast cancer patients with few effective treatment options. Further studies are merited and in progress, especially for our ongoing combination study of Bria-IMT(TM) with KEYTRUDA®.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)